TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:35:13 09/05/2024 BST			5-day change	1st Jan Change
0.245 ^EUR	-3.54%		+0.62%	+6.52%

04-25	TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-23	TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	CI

TME Pharma N.V. announced that it has received ?2.7 million in funding

December 13, 2023

On December 14, 2023, TME Pharma N.V. closed the transaction. The company has issued preferential subscription rights through the issuance of new shares with associated warrants for an amount of ?2.7 million.

Latest news about TME Pharma N.V.

TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	04-23	CI
TME Pharma: Fast Track designation in glioblastoma	04-03	CF
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	04-02	CI
Invest Securities Keeps TME Pharma at Buy, Trims PT	04-02	MT
TME PHARMA : Invest Securities slightly adjusts its target	04-02	CF
TME Pharma: green light from the FDA to launch a ph.II trial	03-05	CF
TME Pharma N.V. Announces FDA Clearance of Investigational New Drug Application for Nox-A12 Phase 2 Trial in Brain Cancer	03-05	CI
TME Pharma: end of convertible bond program	02-09	CF
TME Pharma Raises EUR1.5 Million to Buy Back Convertible Bonds	02-09	MT
TME Pharma N.V. announced that it expects to receive ?1.479999 million in funding	02-08	CI
TME Pharma On Track to Complete Clinical Trial Protocol for Brain Cancer Therapy by Q1	01-10	MT
TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer	01-09	CI
TME Pharma N.V. announced that it has received ?2.7 million in funding	12-13	CI
TME PHARMA : Invest Securities updates its target	11-28	CF
TME Pharma: shares fall after capital increase	11-27	CF
TME Pharma N.V. announced that it expects to receive ?2.7 million in funding	11-23	CI
TME Pharma: reduced loss, visibility until February 2024	30/10/23	CF
TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	28/10/23	CI
TME Pharma: new data in brain cancer	20/10/23	CF
TME PHARMA : Invest Securities confirms its recommendation	12/10/23	CF
TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer	10/10/23	CI
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting	22/09/23	CI
TME Pharma: share price rises on positive data	13/09/23	CF
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer	13/09/23	CI

Chart TME Pharma N.V.

Duration

Period

More charts

Company Profile

TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.

Sector

Biotechnology & Medical Research

Calendar

23/10/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TME PHARMA N.V.	+6.52%	7.76M
MODERNA, INC.	+24.67%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-1.05%	41.52B
CELLTRION, INC.	-5.86%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.86%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.48%	19.26B
BIO-TECHNE CORPORATION	+2.40%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.54%	12.08B
MEDPACE HOLDINGS, INC.	+28.38%	11.98B

Other Biotechnology & Medical Research